תבנית:תרופה/רמיקד - Remicade: הבדלים בין גרסאות

מתוך ויקיתרופות
קפיצה אל: ניווט, חיפוש
Banner.jpg
מ (החלפת טקסט – "|במרשם=כן" ב־"|במרשם=כן")
מ (החלפת טקסט – "|קבוצה פרמקולוגית (ATC)= {{ATC משרד הבריאות|L0" ב־"|קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L0")
 
(14 גרסאות ביניים של 2 משתמשים אינן מוצגות)
שורה 3: שורה 3:
 
|שם באנגלית={{{שם באנגלית|Remicade}}}
 
|שם באנגלית={{{שם באנגלית|Remicade}}}
 
|מרכיב פעיל={{רווח קשיח}}
 
|מרכיב פעיל={{רווח קשיח}}
−
{{{מרכיב פעיל|*[[מרכיב פעיל::Infliximab]] 100.0 MG/VIAL {{כ}}[[ATC code 5::L04AB02]]
+
*[[Infliximab]] 100.0 MG/VIAL {{כ}}[[L04AB02]]
−
*[[מרכיב פעיל::Infliximab]] 100.0 MG/VIAL {{כ}}[[ATC code 5::L04AB02]]
+
|קבוצה פרמקולוגית (ATC)={{ATC משרד הבריאות|L04AB|Tumor necrosis factor alpha (TNF-α) inhibitors}}
−
*[[מרכיב פעיל::Tumor necrosis factor alpha (tnf-a) inhibitors]] L04AB {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::7290008121279]] לא {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::Hochstrasse]] 201, CH-8200 SCHAFFHAUSEN, SWITZERLAND packaging , labelling , lyophilisation , filling , bulk - final formulation {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::Einsteeinweg]] 101, 2333 CB LEIDEN, THE NETHERLANDS batch release {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::60 tuas west drive, singapore ,]] 638413 lyophilisation , filling , bulk - final formulation {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::Industriepark]] 30, HEIST-OP-DEN-BERG, B-2220,BELGIUM packaging , labelling {{כ}}[[ATC code 5::L04AB02]]
+
−
*[[מרכיב פעיל::Infliximab]] 100.0 MG/VIAL {{כ}}[[ATC code 5::L04AB02]]}}}
+
−
|קבוצה פרמקולוגית (ATC)=
+
−
{{{קבוצה פרמקולוגית|[[ATC code 4:: L04AB| ]]{{ATC משרד הבריאות|L04AB|Tumor necrosis factor alpha (TNF-α) inhibitors}}}}}
+
 
|צורת מתן=תוך-ורידי - I.V
 
|צורת מתן=תוך-ורידי - I.V
−
|צורת מינון={{{צורת מינון|POWDER FOR CONCENTRATE FOR INFUSION}}}
+
|צורת מינון=אבקה להכנת תרכיז לאינפוזיה, POWDER FOR CONCENTRATE FOR INFUSION{{ש}}למניעת מינון יתר או הרעלה יש ליטול את התרופה בהתאם למינון המומלץ כפי שמופיע בעלון לצרכן
 
|סל הבריאות=כלול בסל
 
|סל הבריאות=כלול בסל
 
|במרשם=כן
 
|במרשם=כן
 
|התוויה={{{התוויה|<div style="direction:ltr;">- Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies</div>}}}
 
|התוויה={{{התוויה|<div style="direction:ltr;">- Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies</div>}}}
−
|התאמת מינון={{{התאמת מינון|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=2}}}
+
|שם יצרן=[[JANSSEN BIOLOGICS B.V, THE NETHERLAND]]
−
|התוויות נגד={{{התוויות נגד|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=5}}}
+
|שם יצרן מקוצר=[[JANSSEN]]
−
|פרמקודינמיקה={{{פרמקודינמיקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=20}}}
+
|שם בעל הרישום=[[J-C HEALTH CARE LTD]]
−
|פרמקוקינטיקה={{{פרמקוקינטיקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=31}}}
+
−
|שימוש בהריון והנקה={{{שימוש בהריון והנקה|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=11}}}
+
−
|תגובות בין תרופתיות={{{תגובות בין תרופתיות|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=11}}}
+
−
|תופעות לוואי={{{תופעות לוואי|https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf#page=12}}}
+
−
|שם יצרן={{{שם יצרן|[[יצרן::JANSSEN BIOLOGICS B.V, THE NETHERLAND]]}}}
+
−
|שם יצרן מקוצר=[[שם יצרן מקוצר::JANSSEN BIOLOGICS B.V, THE NETHERLAND| ]]
+
−
|שם בעל הרישום={{{שם בעל הרישום|[[בעל רישום::J-C HEALTH CARE LTD]]}}}
+
 
|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::12/2014]]}}}
 
|רישיון מתאריך={{{רישיון מתאריך|[[רישום מתאריך::12/2014]]}}}
−
|תאריך הגשה={{{תאריך הגשה|[[תאריך הגשה::06/2002]]}}}
+
|תאריך הגשה=06/2002
−
|קישור למאגר משרד הבריאות1={{{קישור למאגר משרד הבריאות1|{{מסחרי משרד הבריאות|Remicade|רמיקד}}}}}
+
|קישור למאגר משרד הבריאות1=[https://israeldrugs.health.gov.il/#!/medDetails/137%2018%2029865%2005 רמיקד] במאגר משרד הבריאות
−
|עלון לרופא={{{עלון לרופא|[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_SPC_02_03_16_clean_1457504249563.pdf עלון לרופא]}}}
+
|עלון לרופא={{רווח קשיח}}
−
|עלון לצרכן={{{עלון לצרכן|[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_PIL_02_03_16_app_clean_1457504249563.pdf עלון לצרכן]}}}
+
*[https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum_19_360034021.pdf עלון לרופא 02.03.2021]
−
|החמרות לעלון={{{החמרות לעלון|*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_100mg_injection_03_2016_FORM_1456930021135.doc החמרה לעלון]
+
|עלון לצרכן={{רווח קשיח}}
−
*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_spc_pil_Jun_2013_1371014326339.doc החמרה לעלון]
+
*[https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum_19_360034321.pdf עלון לצרכן עברית 02.03.2021]
−
*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Remicade_spc_pil_Dec_2012_1355378919117.doc החמרה לעלון]
+
*[https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum_10_424674719.pdf כרטיס למטופל רב שפתי 28.02.2019]
−
*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_pil_spc_worsening_Dec.13_1388390092839.doc החמרה לעלון]
+
|החמרות לעלון={{רווח קשיח}}
−
*[https://www.old.health.gov.il/units/pharmacy/trufot/alonim/remicade_spc_pil_Aug-2014_1408273984172.doc החמרה לעלון]}}}
+
*[https://mohpublic.z6.web.core.windows.net/IsraelDrugs/Rishum_19_360035321.pdf החמרה לעלון 02.03.2021]
 +
*[[מדיה:REMICADE - החמרה לעלון - 02.03.2016.pdf|החמרה לעלון 02.03.2016]]
 +
*[[מדיה:REMICADE - החמרה לעלון - 17.08.2014.pdf|החמרה לעלון 17.08.2014]]
 +
*[[מדיה:REMICADE - החמרה לעלון - 30.12.2013.pdf|החמרה לעלון 30.12.2013]]
 +
*[[מדיה:REMICADE - החמרה לעלון - 12.06.2013.pdf|החמרה לעלון 12.06.2013]]
 +
*[[מדיה:REMICADE - החמרה לעלון - 13.12.2012.pdf|החמרה לעלון 13.12.2012]]
 
|מספר רישום={{{מספר רישום|137 18 29865 05}}}
 
|מספר רישום={{{מספר רישום|137 18 29865 05}}}
 
|תאריך עדכון=[[עדכון אחרון::15/05/19]]
 
|תאריך עדכון=[[עדכון אחרון::15/05/19]]
−
|תמונת אריזה={{{תמונת אריזה|}}}
+
|תמונת אריזה=
 
|שיווק הופסק={{{שיווק הופסק|לא}}}
 
|שיווק הופסק={{{שיווק הופסק|לא}}}
−
|שם ללא מינון={{{שם ללא מינון|רמיקד - Remicade}}}
+
|שם ללא מינון=רמיקד - Remicade
 +
|שם ללא מינון באנגלית‎=Remicade
 +
|התאמת מינון=
 +
|התוויות נגד=
 +
|פרמקודינמיקה=
 +
|פרמקוקינטיקה=
 +
|שימוש בהריון והנקה=
 +
|תגובות בין תרופתיות=
 +
|תופעות לוואי=
 +
|חיפוש בוויקירפואה=
 
|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}
 
|ללא קטגוריה={{{ללא קטגוריה|<noinclude>-</noinclude>}}}
 
}}
 
}}
 
<noinclude>{{תרופה/תיעוד}}</noinclude>
 
<noinclude>{{תרופה/תיעוד}}</noinclude>

גרסה אחרונה מתאריך 09:35, 10 באפריל 2022



נתוני תרופה
במרשם RxIcon.png
קבוצה פרמקולוגית (ATC4) L04AB
Tumor necrosis factor alpha (TNF-α) inhibitors
מרכיב פעיל (ATC5)  
צורת מתן תוך-ורידי - I.V
צורת מינון אבקה להכנת תרכיז לאינפוזיה, POWDER FOR CONCENTRATE FOR INFUSION
למניעת מינון יתר או הרעלה יש ליטול את התרופה בהתאם למינון המומלץ כפי שמופיע בעלון לצרכן
התוויה
- Adult :- Crohn's disease: Treatment of moderate to severe active Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. Treatment of fistulising Crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. - Paediatric Crohn's disease: Remicade is indicated for: Treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. Remicade has been studied only in combination with conventional immunosuppressive therapy - Ankylosing spondylitis: Remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy. - Psoriatic arthritis : Remicade is indicated for : Treatment of active and progressive psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. Remicade should be administered : either in combination with methotrexate or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated. - Remicade has been shown to improve physical function in patients with psoriatic arthritis and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease. - Rheumatoid arthritis: Remicade in combination with methotrexate is indicated for the reduction of signs and symptoms as well as the improvement in physical function in: Patients with active disease when the response to disease-modifying drugs including methotrexate has been inadequate. Patients with severe active and progressive disease not previously treated with methotrexate or other DMARDs. In this these patient populations a reduction in the rate of the progression of joint damage as measured by x-ray has been demonstrated - Psoriasis: Remicade is indicated for: Treatment of moderate to severe plaque psoriasis in adults who failed to respond to or who have a contraindication to or are intolerant to other systemic therapy including cyclosporine methotrexate or PUVA. - Ulcerative colitis: Remicade is indicated for: Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to convential therapy including corticosteroids and 6-MP or AZA or who are intolerant to or have medical contraindications for such therapies.- Paediatric ulcerative colitis: Remicade is indicated for treatment of severely active ulcerative colitis, in paediatric patients aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 MP or AZA, or who are intolerant to or have medical contraindications for such therapies
תבנית:נתוני סל/תרופה/רמיקד - Remicade
עלון לרופא והחמרות לעלון

 

 

עלון לצרכן  
ערכים בוויקירפואה ערכים קשורים בוויקירפואה
רמיקד במאגר משרד הבריאות
חיפוש מאמרים -
מידע ברשת -
שם יצרן JANSSEN BIOLOGICS B.V, THE NETHERLAND
שם בעל הרישום J-C HEALTH CARE LTD
רישיון תאריך הגשה: 06/2002. רישיון מתאריך: 12/2014
תאריך עדכון אחרון 15/05/19


תאריך עדכון: 15/05/19 JANSSEN

רמיקד - Remicade true


דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.

  • דף התרופה: רמיקד - Remicade
  • לדריסה ידנית של פרטי התרופה: ניתן לערוך את דף התרופה לעיל. לדוגמה החליפו את: 
{{תרופה/רמיקד - Remicade}}

ב: 

{{תרופה/רמיקד - Remicade
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
מקור: https://wikitrufot.org.il/index.php?title=תבנית:תרופה/רמיקד_-_Remicade&oldid=301755